Corporate ActionJun 22, 2026, 05:02 PM
Eledon Pharma Stockholders Approve 50% Authorized Share Increase
AI Summary
Eledon Pharmaceuticals' stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 300 million to 450 million shares. This decision was made at the Annual Meeting, where stockholders also elected three Class III Directors and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Key Highlights
- Stockholders approved increasing authorized common stock from 300,000,000 to 450,000,000 shares.
- David-Alexandre C. Gros, M.D. elected as Class III Director with 36,633,821 votes For.
- Jan Hillson, M.D. elected as Class III Director with 33,081,275 votes For.
- James Robinson elected as Class III Director with 30,916,807 votes For.
- Deloitte & Touche LLP ratified as independent auditor for 2026 with 56,010,539 votes For.
Price Impact
More from ELDN